SCHEMBL710009

SCHEMBL710009

O=C(O)c1ccc(/C=C/c2nc3ccccc3o2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.64
KMT2A Q03164 5/20 0.64
RAB9A P51151 5/20 0.64
NPC1 O15118 4/20 0.64
ALDH1A1 P00352 3/20 0.63
HPGD P15428 3/20 0.63
KDM4E B2RXH2 2/20 0.63
CYP2D6 P10635 1/20 0.63
HDAC3 O15379 1/20 0.59
HDAC4 P56524 1/20 0.59
HDAC1 Q13547 1/20 0.59
HDAC7 Q8WUI4 1/20 0.59
HDAC2 Q92769 1/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC11 Q96DB2 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
HDAC9 Q9UKV0 1/20 0.59
HDAC5 Q9UQL6 1/20 0.59
MAPT P10636 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL317883 1.00 MEN1 (0.64) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL156861 0.85 SNCA (0.64) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL61657 0.85 SNCA (0.64) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4826174 0.84 RAB9A (0.66) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4826178 0.84 RAB9A (0.66) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL8155474 0.83 NPC1 (0.60) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL6607138 0.82 MEN1 (0.63) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL6607140 0.82 MEN1 (0.63) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL22360047 0.82 MEN1 (0.63) MEN1KMT2ARAB9ANPC1ALDH1A1
Benzoic Acid SCHEMBL11551717 0.82 KMT2A (0.48) MEN1KMT2ARAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB MEN1 3997/4885KMT2A 3382/4885RAB9A 4723/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 MEN1 3163/4885KMT2A 3744/4885RAB9A 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.